How we do business
GSK has been a significant supporter of The George Institute for Global Health for a number of years and we’ve recently contributed $161,000 to support a research fellow in respiratory medicine.
Most of us take breathing for granted. It’s an automatic activity that we don’t need to think about. But imagine if every breath you took was a struggle; imagine waking up in the night wheezing and short of breath.
Can you imagine what it would feel like to take a breath when your lungs were already full of air? This is a feeling people with Chronic Obstructive Pulmonary Disease (COPD) may live with every day of their lives.
Over 1.4 million Australians are living with Chronic Obstructive Pulmonary Disease, or COPD, with as many as one in 20 people over the age of 55 affected by the condition. Although understanding of COPD has improved significantly in recent years, we are constantly seeking new avenues to explore in our relentless pursuit for better breathing.
Access to healthcare
A global alliance led by GSK and Monash University promises to fast-track delivery of oxytocin to mothers in developing countries